FLJ10489 Inhibitors
The FLJ10489 Inhibitors chemical class comprises a diverse array of compounds targeting key components of signaling pathways crucial for the activation and regulation of FLJ10489. These inhibitors act on various kinases and signaling molecules, disrupting cellular cascades involved in FLJ10489 expression. Wortmannin and LY294002 inhibit FLJ10489 by targeting phosphoinositide 3-kinase (PI3K), a central player in the PI3K/AKT/mTOR pathway. Rapamycin indirectly impacts FLJ10489 by inhibiting mTOR, a downstream effector in the same pathway. PD98059 and U0126 disrupt the MAPK pathway by inhibiting MEK1/2, influencing FLJ10489 through upstream signals. SP600125 and SB203580 target JNK and p38 MAPK, respectively, affecting FLJ10489 through MAPK pathway modulation. AG-490 inhibits JAK2 in the JAK/STAT pathway, impacting FLJ10489 indirectly. SB216763 targets GSK-3β in the Wnt/β-catenin pathway, affecting FLJ10489 regulation. BAY 11-7082 inhibits NF-κB, influencing FLJ10489 indirectly through NF-κB-mediated cellular processes. BX795 targets PDK1 in the PI3K/AKT/mTOR pathway, disrupting FLJ10489 activation through pathway interference. This diverse chemical class collectively interferes with multiple signaling pathways, highlighting potential strategies for modulating FLJ10489 expression in cellular contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits FLJ10489 by targeting phosphoinositide 3-kinase (PI3K), disrupting the PI3K/AKT/mTOR signaling pathway essential for FLJ10489 activation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 acts as a potent inhibitor of PI3K, suppressing FLJ10489 by interrupting the PI3K/AKT/mTOR pathway that plays a pivotal role in FLJ10489 regulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits FLJ10489 indirectly by targeting mTOR, a downstream effector of the PI3K/AKT/mTOR cascade, disrupting the signaling network essential for FLJ10489. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK1, a kinase upstream of ERK1/2. By disrupting the MAPK pathway, it indirectly hampers FLJ10489 activation, affecting its downstream signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2 and disrupts the MAPK pathway, indirectly influencing FLJ10489 by interfering with its upstream regulatory signals. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, a component of the MAPK pathway. By interrupting this pathway, it indirectly suppresses FLJ10489, affecting its downstream cellular responses. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAPK, impacting the MAPK pathway. Its action indirectly influences FLJ10489 by disrupting the signaling cascade essential for FLJ10489 activation. | ||||||
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $82.00 $323.00 $219.00 $85.00 | 35 | |
AG-490 inhibits JAK2, affecting the JAK/STAT pathway. This indirectly influences FLJ10489 by disrupting the JAK/STAT signaling cascade critical for FLJ10489 activation. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $70.00 $198.00 | 18 | |
SB216763 inhibits GSK-3β, disrupting the Wnt/β-catenin pathway. Its action indirectly impacts FLJ10489, as the Wnt/β-catenin pathway plays a role in FLJ10489 regulation. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
BAY 11-7082 inhibits NF-κB activation, indirectly affecting FLJ10489, as NF-κB is involved in regulating various cellular processes, including those related to FLJ10489. | ||||||